[13N]Ammonia and l-[amide-13N]glutamine metabolism in glutaminase-sensitive and glutaminase-resistant murine tumors

• Published in: Biochimica et biophysica acta Vol. 843; no. 1-2; pp. 37 - 48
• Main Authors: Rosenspire, Karen C., Gelbard, Alan S., Cooper, Arthur J.L., Schmid, Franz A., Roberts, Joseph
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier 22.11.1985; North-Holland
• Subjects: Amino Acids - analysis; Ammonia - metabolism; Animals; Antineoplastic agents; Biological and medical sciences; Blood Volume; Drug Resistance; Female; gamma-Glutamyltransferase - metabolism; General aspects; Glutamate-Ammonia Ligase - metabolism; Glutaminase - therapeutic use; Glutamine - metabolism; In Vitro Techniques; Liver - metabolism; Medical sciences; Mice; Pharmacology. Drug treatments; Sarcoma 180 - drug therapy; Sarcoma 180 - metabolism; Sarcoma, Experimental - drug therapy; Sarcoma, Experimental - metabolism; Urea - biosynthesis; Urea - blood; Antineoplastic agent; Enzyme; Rodentia; Metabolism; Glutaminase; Ammonia; Vertebrata; Chemotherapy; Mammalia; Sensitivity resistance; Mouse; Animal; Tumor; Glutamine
• ISSN: 0304-4165; 0006-3002; 1878-2434
• DOI: 10.1016/0304-4165(85)90047-9

The short-term metabolic fate of labeled nitrogen derived from [13N]ammonia or from L-[amide-13N]glutamine was determined in murine tumors known to be resistant (Ridgeway Osteogenic Sarcoma (ROS] or sensitive (Sarcoma-180 (S-180)) to glutaminase therapy. At 5 min after intraperitoneal injection of [13N]ammonia or of L-[amide-13N]glutamine, only about 0.7% of the label recovered in both tumors was in protein and nucleic acid. After [13N]ammonia administration, most of the label (over 80%) was in a metabolized form; a large portion of this metabolized label (50-57%) was in the urea fraction with a smaller amount in glutamine (37-42%). The major short-term fate of label derived from L-[amide-13N]glutamine was incorporation into components of the urea cycle with smaller amounts in the acidic metabolites and in acidic amino acids. No labeled urea was found during in vitro studies in which S-180 tumor slices were incubated with [13N]ammonia, suggesting that the [13N]urea formed in the tumor in the in vivo experiments was not due to de novo synthesis through carbamyl phosphate in the tumor. Both tumors exhibited very low glutamine synthetase activity. Following glutaminase treatment, glutamine synthetase and gamma-glutamyltransferase activities, while remaining low, increased in the resistant tumor but not in the sensitive tumor; this increase may be related to the insensitivity of the ROS tumor toward glutaminase treatment.